Watch UTMD. Know when insiders buy.
One email the day a filing lands. Free.
UTMD
UTAH MEDICAL PRODUCTS INC
74.13
−0.22 −0.30%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
9
FLAG · shorts 9
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $236MP/E 22.6DIV YIELD —FCF YIELD 4.85%REV TTM $36.1M −7.0%NET INCOME $10.5M −16.5%NET CASH $87.5M52W 53.80 – 76.66SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $8.5M | −14.3% | 55.8% | $2.6M | $2.7M | −11.9% | 0.84 | $1.4M | $134K | $1.2M | Aug 12 |
| Q1 2026 · Mar 31 | $8.7M | −10.2% | 60.6% | $2.6M | $2.6M | −14.4% | 0.82 | $3.1M | $130K | $3M | Aug 12 |
| Q4 2025 · Dec 31 | $9M | −1.2% | 58.2% | $2.4M | $2.6M | −11.6% | 0.80 | $3.5M | $109K | $3.4M | Mar 27 |
| Q3 2025 · Sep 30 | $9.8M | −1.9% | 57.1% | $2.6M | $2.6M | −26.2% | 0.82 | $3.9M | $27K | $3.9M | Mar 27 |
| Q2 2025 · Jun 30 | $10M | −4.3% | 56.2% | $3.2M | $3M | −11.7% | 0.94 | $2.9M | $51K | $2.8M | Aug 12 |
| Q1 2025 · Mar 31 | $9.7M | −14.4% | 57.0% | $3.2M | $3M | −23.1% | 0.92 | $4.5M | $184K | $4.3M | Aug 12 |
| Q4 2024 · Dec 31 | $9.2M | −25.8% | 58.1% | $2.9M | $2.9M | −32.3% | 0.86 | $2.9M | $9K | $2.9M | Mar 27 |
| Q3 2024 · Sep 30 | $10M | −20.0% | 58.0% | $3.3M | $3.6M | −9.5% | 1.03 | $3.9M | $89K | $3.8M | Mar 27 |
| Q2 2024 · Jun 30 | $10.4M | — | 60.1% | $3.4M | $3.5M | — | 0.98 | $2.8M | $110K | $2.7M | Mar 27 |
| Q1 2024 · Mar 31 | $11.3M | — | 59.7% | $3.9M | $4M | — | 1.09 | $5.3M | $22K | $5.3M | Mar 27 |
| Q4 2023 · Dec 31 | $12.3M | — | 57.6% | $3.9M | $4.3M | — | 1.18 | $5.3M | $90K | $5.2M | Mar 27 |
| Q3 2023 · Sep 30 | $12.5M | — | 58.8% | $4M | $3.9M | — | 1.08 | $5.1M | $186K | $4.9M | Mar 27 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $38.5M | 57.1% | $11.4M | $11.3M | 29.3% | 3.48 | $14.7M | $371K | $14.3M | $8.4M | $4M |
| FY2024 · to Dec 31 | $40.9M | 59.0% | $13.6M | $13.9M | 33.9% | 3.96 | $14.8M | $230K | $14.6M | $20M | $4.3M |
| FY2023 · to Dec 31 | $50.2M | 59.8% | $16.8M | $16.6M | 33.1% | 4.57 | $22.3M | $639K | $21.6M | $0 | $4.3M |
| FY2022 · to Dec 31 | $52.3M | 61.6% | $19.8M | $16.5M | 31.5% | 4.52 | $21.1M | $809K | $20.3M | $2.5M | $3.2M |
| FY2021 · to Dec 31 | $49.1M | 63.0% | $18.9M | $14.8M | 30.1% | 4.04 | $21.2M | $552K | $20.7M | $0 | $11.5M |
| FY2020 · to Dec 31 | $42.2M | 60.6% | $13.7M | $10.8M | 25.6% | 2.94 | $20.1M | $860K | $19.3M | $7M | $4.1M |
Every number comes from UTAH MEDICAL PRODUCTS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.